Plain-English translation of NCT05412004 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Obesity research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial tested , a new medication given as a weekly injection, to see if it could help people with obstructive sleep apnea (a condition where breathing stops and starts during sleep) and obesity. Researchers studied the medication's effectiveness and safety in two groups: people who were not using positive airway pressure (PAP) therapy machines and people who were using them. The trial investigated whether this treatment could improve sleep apnea symptoms and help with weight loss.
Many people with sleep apnea and excess weight either cannot or do not want to use PAP machines, which are the standard treatment. Researchers wanted to test whether this medication could offer an alternative or additional option to help manage both conditions at the same time.
Participants received either the new medication or a placebo (inactive injection) once per week as a shot under the skin for 52 weeks. The medication dose was gradually increased over the first few weeks to reach the highest tolerated dose. Participants attended regular visits to be monitored for safety and effectiveness, and underwent sleep studies at the beginning and end of the trial to measure changes in their sleep apnea. Throughout the year-long study, researchers tracked participants' breathing patterns, weight, and overall health.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States